Unicycive Therapeutics, INC 10-Q quarterly reports

Unicycive Therapeutics reported a significant increase in net loss for the six months ended June 30, 2026, alongside a setback in its OLC New Drug Application, though it bolstered its cash position through common stock sales.

Unicycive Therapeutics reported a wider net loss for Q1 2026, driven by increased general and administrative expenses, despite a decrease in R&D spending.

Unicycive Therapeutics reported a reduced net loss and increased cash reserves in Q3 2025, while planning to resubmit its Oxylanthanum Carbonate NDA by year-end following an FDA meeting.

Unicycive Therapeutics, an early-stage biotech, reported a net loss for Q2 2025 and increased cash burn from operations, despite a recent $12.2 million equity raise and progress in its drug development pipeline.

Unicycive Therapeutics reports a net income of $0.6 million for Q1 2025, primarily driven by changes in the fair value of warrant liabilities, while expressing concerns about its ability to continue as a going concern.

Unicycive Therapeutics reports a net loss of $4.1 million for the third quarter of 2024, alongside updates on their drug development programs and recent financing activities.

Unicycive Therapeutics has amended its manufacturing agreement with Shilpa Medicare and reported its financial results for the second quarter of 2024, showing a significant increase in cash and a net loss.

Unicycive Therapeutics reported a net loss of $20.9 million for the first quarter of 2024, despite securing $50 million in gross proceeds through a private placement.